Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice

M Pinter, B Scheiner, DJ Pinato - The lancet Gastroenterology & …, 2023 - thelancet.com
Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …

Locoregional treatments in cholangiocarcinoma and combined hepatocellular cholangiocarcinoma

M Renzulli, D Ramai, J Singh, S Sinha, N Brandi… - Cancers, 2021 - mdpi.com
Simple Summary Cholangiocarcinoma is an aggressive primary cancer of the biliary tree.
Combined hepatocellular cholangiocarcinoma is also a primary liver malignancy but …

[HTML][HTML] Combined hepatocellular-cholangiocarcinoma: biology, diagnosis, and management

L Ye, JS Schneider, N Ben Khaled, P Schirmacher… - Liver Cancer, 2024 - karger.com
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-iCCA) is a rare type of
primary liver cancer displaying characteristics of both hepatocytic and cholangiocytic …

Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular‐cholangiocarcinoma

EJ Kim, C Yoo, HJ Kang, KP Kim, MH Ryu… - Liver …, 2021 - Wiley Online Library
Abstract Background & Aims The optimal systemic chemotherapy for combined
hepatocellular‐cholangiocarcinoma (cHCC‐CCA) has not yet been defined. The definition …

CEUS and CT/MRI LI-RADS in association with serum biomarkers for differentiation of combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma

Y Zhou, S Yin, L Zhao, X Zhang, M Li, J Ding… - Frontiers in …, 2022 - frontiersin.org
Background Combined Hepatocellular-cholangiocarcinoma (cHCC-CCAs) are with both
unambiguously differentiated hepatocellular and biliary components. cHCC-CCAs show …

The emerging role of immunotherapy in intrahepatic cholangiocarcinoma

O Fiste, I Ntanasis-Stathopoulos, M Gavriatopoulou… - Vaccines, 2021 - mdpi.com
Biliary tract cancer, and intrahepatic cholangiocarcinoma (iCC) in particular, represents a
rather uncommon, highly aggressive malignancy with unfavorable prognosis. Therapeutic …

[HTML][HTML] The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and …

Y Tang, L Wang, F Teng, T Zhang, Y Zhao… - International Journal of …, 2021 - ncbi.nlm.nih.gov
Background: Clinical characteristics and prognosis among combined hepatocellular
carcinoma (HCC) and cholangiocarcinoma (cHCC-CC) with HCC and intrahepatic …

[PDF][PDF] Use of Contrast‐Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response.

MF Meloni, G Francica, J Chiang… - Journal of Ultrasound …, 2021 - researchgate.net
Compared to contrast-enhanced computed tomography and contrastenhanced magnetic
resonance imaging, CEUS presents several advantages in imaging HCC, including real …

Clinicopathologic features, treatment, survival, and prognostic factors of combined hepatocellular and cholangiocarcinoma: A nomogram development based on …

YW Zhou, QF Li, YY Chen, K Wang, D Pu… - European Journal of …, 2022 - Elsevier
Purpose The aim of the study was to comprehensively understand the combined
hepatocellular and cholangiocarcinoma (CHC) and develop a nomogram for prognostic …

Perioperative and oncologic outcomes of laparoscopic versus open liver resection for combined hepatocellular-cholangiocarcinoma: a propensity score matching …

DJ Song, K Zhu, J Tan, JB Cai, MZ Lv, J Hu, ZB Ding… - Surgical …, 2023 - Springer
Background Laparoscopic liver resection (LLR) has now been established as a safe and
minimally invasive technique that is deemed feasible for treating hepatocellular carcinoma …